Citius Oncology, Inc.
CTORAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 23, 2025 | Maxim Group | Michael Okunewitch | $6.00(+237%) | $1.78 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | upgrade | Hold →Buy | Sep 23, 2025 |
| Maxim Group | downgrade | Buy →Hold | May 23, 2025 |
| EF Hutton | maintain | Buy | Aug 13, 2024 |
Earnings History
Next report: Dec 17, 2026 · EPS est. $-0.07| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.08 | $-0.07 | $1.5M | $2.5M |
| May 15, 2026 | $-0.27 | $-0.01 | $1.7M | $7.0M |
| Feb 13, 2026 | $-0.06 | $-0.04 | $3.9M | $4.4M |
| Dec 23, 2025 | $-0.06 | $-0.06 | — | — |
| Aug 12, 2025 | $-0.08 | $-0.15 | — | — |
| May 14, 2025 | $-0.11 | $-0.09 | — | $5.7M |
| Feb 14, 2025 | $-0.09 | $-0.06 | — | — |
| Dec 27, 2024 | $-0.07 | $-0.08 | — | — |
News
Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures CRANFORD, N.J., Nov. 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR) today announced health-related quality of life (HRQoL) results from pivotal Study 302 ( NCT01871727…
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIRÂ Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026.
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference CRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one inves…
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference CRANFORD, N.J.
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today repo…
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering LYMPHIR ordered by 44 institutions since launch CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas…
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.